Resmetirom
Payments companies reported to CMS as associated with Resmetirom. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Resmetirom, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Resmetirom
These are the largest totals companies reported as associated with Resmetirom. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Naim Alkhouri | Westlake, OH | Gastroenterology (Internal Medicine) | $6,347.74 |
| Mazen Noureddin | Houston, TX | Gastroenterology (Internal Medicine) | $4,274.39 |
| Alina Allen | Rochester, MN | Gastroenterology (Internal Medicine) | $4,267.15 |
| Mary Rinella | Chicago, IL | Gastroenterology (Internal Medicine) | $4,120.80 |
| Rohit Loomba | La Jolla, CA | Internal Medicine | $2,695.60 |
| Kris Kowdley | Seattle, WA | Gastroenterology (Internal Medicine) | $2,415.01 |
| John Bucuvalas | New York, NY | Pediatric Gastroenterology | $2,323.19 |
| Miriam Vos | Grand Rapids, MI | Pediatric Gastroenterology | $2,285.59 |
| Hashem El-Serag | Houston, TX | Gastroenterology (Internal Medicine) | $2,250.52 |
| Dina Halegoua De Marzio | Philadelphia, PA | Gastroenterology (Internal Medicine) | $2,125.41 |
Prescribed Resmetirom?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.